Evidence map›Paper›PMID 41697698›Full record

ArticleJAMA network open2026

Electronic Health Record Alerts for Early Human Papillomavirus Vaccination.

Tina Kumra, Yongyi Lu, Steve Blash, Michael Crocetti, Yu Bin Na, Laura Prichett, Anna Beavis, Jenell S Coleman

Abstract read
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tina KumraDepartment of Pediatrics, Johns Hopkins Community Physicians, Baltimore, Maryland.
Yongyi LuDepartment of Gynecology and Obstetrics, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Steve BlashDepartment of Family Medicine, Johns Hopkins Community Physicians, Hagerstown, Maryland.
Michael CrocettiDepartment of Pediatrics, Johns Hopkins Community Physicians, Baltimore, Maryland.
Yu Bin NaDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Laura PrichettDepartment of Pediatrics, Johns Hopkins Community Physicians, Baltimore, Maryland.
Anna BeavisDivision of Gynecology Oncology, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, California.
Jenell S ColemanDepartment of Gynecology and Obstetrics, School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Despite recommendations to begin human papillomavirus (HPV) vaccination as early as 9 years of age, uptake remains low. Objectives: To compare early HPV vaccine initiation between 2 interventions, compare vaccine completion rates between youths initiating HPV vaccination at 9 to 10 vs 11 to 14 years of age, and identify factors associated with early HPV vaccination initiation and series completion. Design, Setting, and Participants: This retrospective quality improvement study was conducted from January 1, 2019, to December 31, 2023. The study analyzed a quality improvement project using descriptive statistics and survival analyses. Youths aged 9 to 14 years with no prior HPV vaccination, who had at least 1 in-person visit, and who had complete electronic health record (EHR) data were included. The study took place at 21 US outpatient primary care sites within a large health system. Site assignments were based on patient volume and geographic location (urban and rural). Exposures: An EHR best practice alert (BPA) recommending HPV vaccination beginning at 9 years of age implemented with or without an added clinician education component. Main Outcomes and Measures: The primary outcome was HPV vaccine initiation at 9 to 10 years of age. Secondary outcomes included vaccine series completion within 2 years after initiation and factors associated with early initiation and completion. Outcomes were measured using EHR-recorded vaccination status and timing. Results: A total of 15 743 eligible patients (mean [IQR] age, 9.9 [9.0-11.0] years; 7946 [50.5%] male; 1260 [8.0%] Asian, 5082 [32.3%] Black or African American, 7621 [48.4%] White, 420 [2.7%] unknown race, and 1360 [8.6%] other race, including American Indian or Alaska Native, Guamanian or Chamorro, and Native Hawaiian or Other Pacific Islander) participated in the study. Overall, 10 102 (64.2%) initiated and 5198 (33.0%) completed the vaccine series. In the group aged 9 to 10 years, the BPA plus education arm had a significantly higher likelihood of initiating vaccination than the BPA-only arm (adjusted hazard ratio, 1.39; 95% CI, 1.17-1.65; P < .001) compared with the group aged 11 to 14 years. Completion increased from 16 (2.2%) to 464 (19.6%) among youths aged 9 to 10 years and from 183 (13.9%) to 323 (66.6%) among youths age 11 to 14 years. By year 3, the group aged 9 to 10 years had a higher cumulative completion rate than the group aged 11 to 14 years (3899 [33.9%] vs 1299 [30.7%], P < .001). Black or African American race and public insurance were associated with HPV vaccine initiation and completion. Conclusions and Relevance: In this quality improvement study of early HPV vaccine initiation, an EHR BPA combined with education was associated with a higher likelihood of early HPV vaccination. Delayed but meaningful improvements in series completion were observed among early initiators.

Indexed as

Electronic Health RecordsPapillomavirus InfectionsPapillomavirus VaccinesVaccinationAdolescentChildFemaleHuman Papillomavirus VirusesHumansMaleQuality ImprovementRetrospective StudiesUnited StatesPapillomavirus Vaccines

Identifiers

PMID41697698
PMCPMC12910398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.